AI assistant
RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2022
Feb 15, 2022
30849_dirs_2022-02-15_d71cb9e7-e7ed-4e9f-b06a-d087563972ea.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2022-02-11
Reporting Person: Chien Jennifer (EVP, Head of North America)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-02-11 | Common Stock | M | 2032 | — | Acquired | 2032 | Direct |
| 2022-02-15 | Common Stock | S | 722 | $6.10 | Disposed | 1310 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-02-11 | Restricted Stock Units | $ | M | 2032 | Disposed | Common Stock (2032) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported Restricted Share Units.
F3: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date.